Basic Klaricid Information

• INN (International Nonproprietary Name): Clarithromycin
• Brand Names Available In United Kingdom: Klacid (marketed in Europe, including the UK); multiple generics sold under the INN clarithromycin.
• ATC Code: J01FA09
• Forms & Dosages: Immediate‑release tablets 250 mg and 500 mg; extended‑release tablets 500 mg; granules for oral suspension 125 mg/5 mL and 250 mg/5 mL supplied as bottles for reconstitution (50–100 mL).
• Manufacturers In United Kingdom: Klacid and generics supplied by European manufacturers including Abbott, Mylan and Teva (local distributors supply branded and generic clarithromycin).
• Registration Status In United Kingdom: Marketed in the UK as Klacid and as generic clarithromycin; specific MHRA summary data not specified in the supplied product information.
• OTC / Rx Classification: Prescription (Rx Only) in nearly all countries.

Key Findings From Recent Trials

Major 2022–2025 Studies

Are there big changes clinicians should know about after recent surveillance and pooled analyses?

Recent observational surveillance and pooled analyses from 2022–2025 are the dominant evidence base in this period.

These studies focused on community respiratory pathogens, Helicobacter pylori, and safety surveillance datasets relevant to clarithromycin and other macrolides.

Randomised controlled trials in the contemporary resistance era were fewer in number than surveillance reports and meta‑analyses.

The UK emphasis in these reports is on local susceptibility patterns and stewardship rather than new efficacy claims for clarithromycin tablets or suspension.

Main Outcomes

What did the trials and pooled analyses conclude about effectiveness?

Surveillance consistently showed rising clarithromycin resistance among common respiratory pathogens and H. pylori, reducing the usefulness of clarithromycin monotherapy for some indications.

Comparative analyses reported similar short‑term symptom relief between clarithromycin and other macrolides or doxycycline when organisms were susceptible.

Clinical effectiveness for community‑acquired pneumonia, bronchitis and sinusitis remains acceptable where local susceptibility supports macrolide use.

Guidance increasingly recommends checking local resistance before empirical macrolide prescribing for chest infections.

Safety Observations

Which safety issues stood out between 2022 and 2025?

Safety reviews and pharmacovigilance data reinforced persistent signals for QT prolongation risk and CYP3A4‑mediated drug interactions with clarithromycin.

Regulatory summaries across the period reaffirmed prescription‑only status and emphasised monitoring for hepatotoxicity and cardiac events.

Analyses highlighted drug–drug interaction harms (for example involving colchicine in hepatic or renal impairment) and recommended adherence to contraindications.

Overall evidence level was primarily observational, surveillance and pooled analyses rather than a fresh series of randomised placebo‑controlled trials.

Clinical Mechanism Of Action

Layman’s Explanation

How does clarithromycin work in plain terms?

Clarithromycin stops bacteria making the proteins they need to grow and multiply, which slows the infection and gives the immune system a chance to clear the germs.

This effect explains why many patients with susceptible chest infections feel better within 48–72 hours of starting clarithromycin tablets or suspension.

Scientific Breakdown

What is the precise antibacterial action of clarithromycin?

Clarithromycin binds to the bacterial 50S ribosomal subunit and inhibits peptidyl transferase and translocation steps of protein synthesis.

The action is primarily bacteriostatic but can be bactericidal at higher concentrations against some organisms.

Clarithromycin is well absorbed orally and concentrates in respiratory tissues, which helps explain clinical benefit for respiratory tract infections.

Active Metabolite Role

Does clarithromycin have an active metabolite that matters clinically?

Yes, clarithromycin is metabolised partly to a 14‑hydroxy active metabolite that contributes to overall antimicrobial activity.

This metabolite is particularly important for activity against Haemophilus species and some Helicobacter pylori strains.

Pharmacokinetic effects also explain key drug interactions because clarithromycin inhibits hepatic CYP3A4, altering levels of co‑medications.

Scope Of Approved & Off‑Label Use

United Kingdom Approvals

What conditions is clarithromycin licensed for in UK practice?

Clarithromycin is licensed for community‑acquired pneumonia, bronchitis, pharyngitis/tonsillitis, acute maxillary sinusitis, skin and soft tissue infections, and as part of H. pylori triple therapy.

It is also used in the treatment and prevention of Mycobacterium avium complex (MAC) in HIV when combined with other agents.

Available forms include immediate‑release tablets 250 mg and 500 mg, extended‑release 500 mg tablets and granules for suspension 125/5 mL and 250/5 mL.

Notable Off‑Label Trends

When do clinicians use clarithromycin off‑label?

Clarithromycin is often chosen empirically for patients with penicillin allergy who need atypical coverage for a chest infection.

It is also used for chronic bronchitic exacerbations where atypical pathogens are suspected, and as part of specialist regimens for atypical mycobacteria.

Because clarithromycin resistance in H. pylori and respiratory pathogens is rising, off‑label empirical use should follow local susceptibility and macrolide stewardship guidance.

Dosage Strategy

General Dosing

What are the standard dosing options for adults and children?

Adults typically take immediate‑release clarithromycin tablets 250–500 mg every 12 hours for 7–14 days, or extended‑release 500 mg once daily when indicated.

Paediatric dosing uses the suspension at 7.5 mg/kg every 12 hours with a maximum single dose of 500 mg.

Choose formulation to suit adherence: twice‑daily IR for short courses or once‑daily ER for convenience where the indication allows.

Condition‑Specific Dosing

How should doses be adjusted by indication and organ function?

For community‑acquired pneumonia, bronchitis and skin infections use 250–500 mg every 12 hours for 7–14 days depending on severity and organism.

Acute maxillary sinusitis is commonly treated with 500 mg every 12 hours for 14 days.

H. pylori triple therapy usually uses 500 mg every 12 hours with amoxicillin and a PPI for 7–14 days.

For MAC in HIV, clarithromycin is given 500 mg every 12 hours as part of combination regimens per specialist protocols.

In renal impairment with CrCl <30 mL/min halve the normal dose or double the dosing interval and avoid in severe hepatic impairment.

Safety Protocols

Contraindications

Who must not receive clarithromycin?

Absolute contraindications include hypersensitivity to clarithromycin or other macrolides.

Also avoid clarithromycin in patients with a history of cholestatic jaundice or hepatic dysfunction attributed to the drug.

Co‑administration with colchicine is contraindicated in patients with hepatic or renal impairment because of serious interaction risk.

Use caution in patients with known QT prolongation, bradyarrhythmias, severe myasthenia gravis, significant hepatic or renal impairment, or when potent CYP3A4 substrates are co‑prescribed.

Adverse Effects

What side effects should clinicians and patients expect?

Common mild or moderate adverse events are gastrointestinal: nausea, diarrhoea, abdominal pain and vomiting.

Other frequent effects include a metallic or sour taste, headache and transient elevations in liver enzymes.

Less common concerns include transient hearing changes at high doses, rash, and occasional neuropsychiatric symptoms such as insomnia and anxiety.

For prolonged therapy monitor liver function tests and review ECG when other QT‑prolonging agents are present, and report severe hepatic injury or arrhythmias via the Yellow Card scheme.

Interaction Mapping

Food Interactions

Will food change clarithromycin absorption?

Overall absorption is not markedly affected by food for clarithromycin, but check the product information for specific guidance on extended‑release tablets.

Patients may take most formulations with or without food unless the local product leaflet advises otherwise.

Drug Combinations To Avoid

Which drug interactions are clinically important?

Clarithromycin is a moderate to strong inhibitor of CYP3A4 and can raise plasma levels of many medicines.

Major examples include simvastatin and lovastatin (risk of myopathy and rhabdomyolysis), certain calcium channel blockers and some benzodiazepines.

Co‑prescription with colchicine is contraindicated in patients with hepatic or renal impairment due to life‑threatening toxicity risk.

QT‑prolonging drugs such as some antiarrhythmics, selected antipsychotics and fluoroquinolones increase arrhythmia risk when combined with clarithromycin.

Mitigation steps include reviewing the full medication list, switching statins to pravastatin or rosuvastatin where necessary, and avoiding contraindicated combinations.

Patient Experience Analysis

Survey Data

What do patients say about clarithromycin treatment?

UK and international surveys report that many patients notice symptomatic relief of respiratory symptoms within 48–72 hours when the infecting organism is susceptible.

Gastrointestinal adverse effects and the characteristic metallic taste are commonly reported reasons for discontinuation or non‑adherence.

Short courses and clear counselling about what to expect improve completion rates for clarithromycin 250mg and 500mg tablets or suspension.

Forum Trends

How do online communities discuss clarithromycin?

Patients often ask about brand names such as Klacid versus generic clarithromycin and share concerns about interactions with statins or colchicine.

Many discuss dosing confusion for children and request clarification on the paediatric clarithromycin suspension dose and how to measure it accurately.

Longer acting ER formulations are seen by patients as easier to take, but cost and interaction profiles influence clinician recommendations and adherence.

Distribution & Pricing Landscape

Brand & Generic Supply

Where does clarithromycin come from and how is it packaged?

Clarithromycin is marketed globally under brands such as Klacid in Europe and Biaxin historically in North America, with many generics supplied by manufacturers including Mylan, Teva and local producers.

In the UK the product is available as branded Klacid and multiple generics in immediate‑release and extended‑release tablets and oral suspensions.

Typical packaging includes blister packs for tablets (14–42 tablets for IR; 7–14 for ER) and bottles for granules to reconstitute into 50–100 mL suspensions in 125 mg/5 mL or 250 mg/5 mL strengths.

UK Market Considerations

How do pricing and supply affect prescribing in the United Kingdom?

Generics have reduced cost and NHS prescribing typically favours generic clarithromycin where clinically appropriate.

Check local formularies for preferred brands and supply alerts for shortages; some IV preparations are not widely available in all markets.

In our online pharmacy, klaricid is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Alternative Options

Comparison Summary

Which antibiotics are commonly chosen instead of clarithromycin?

Alternatives include azithromycin, erythromycin, doxycycline, amoxicillin‑clavulanate and levofloxacin depending on the indication and patient factors.

Choice should consider likely pathogens, local resistance, patient allergy status and comorbidities such as QT risk or pregnancy.

Pros And Cons

What are the practical advantages and drawbacks of the main alternatives?

Azithromycin offers once‑daily dosing and shorter courses but has rising resistance and distinct tissue kinetics compared with clarithromycin.

Erythromycin is older and causes more gastrointestinal intolerance while sharing CYP3A4 interactions.

Doxycycline covers atypical pathogens with minimal CYP interactions but is contraindicated in pregnancy and young children and causes photosensitivity.

Amoxicillin‑clavulanate gives broad beta‑lactam coverage for typical bacteria but lacks atypical coverage and is not suitable for true penicillin allergy.

Levofloxacin provides potent respiratory coverage but carries higher risks of tendinopathy, QT effects and has stewardship limitations.

Regulatory Status

International Approvals

Which regulators have approved clarithromycin?

Clarithromycin is approved by major regulators including the FDA and EMA, and is marketed under various brand names worldwide.

National registrations exist across many countries, with public summaries recorded in several national databases.

UK Regulatory Position

What is the UK position on clarithromycin safety and licensing?

Clarithromycin remains a prescription‑only medicine and label warnings reflect hepatic injury risk and significant drug interactions via CYP3A4.

Regulators continue post‑marketing surveillance focusing on cardiac and hepatic adverse events and provide stewardship guidance aligned with antimicrobial policy.

Consolidated FAQ

Quick Answers For Clinicians And Patients

Is clarithromycin effective for chest infections?

Yes, when pathogens are susceptible; typical dosing is 250–500 mg twice daily, but rising macrolide resistance means local susceptibility should guide empirical use.

Can I prescribe in pregnancy?

Use with caution; alternatives with more established pregnancy safety data are often preferred in early pregnancy and a risk–benefit discussion is required.

What about children?

Use the suspension and dose at 7.5 mg/kg every 12 hours up to a maximum of 500 mg per dose.

How are drug interactions managed?

Review the full medication list, avoid contraindicated combinations such as colchicine in hepatic or renal impairment, and consider switching statins to agents with lower CYP3A4 metabolism.

How should the medicine be stored?

Store tablets below 25°C; reconstituted suspension should be refrigerated at 2–8°C and discarded after 14 days.

For further queries consult local formularies and MHRA product information.

Visual Guide

Suggested Diagrams And Infographics

Which visuals help clinicians and patients most?

Create a two‑panel mechanism infographic showing clarithromycin binding to the 50S ribosome and the contribution of the 14‑hydroxy metabolite.

Include a dosing algorithm chart with age/weight‑based paediatric dosing, adult IR versus ER choices and a renal adjustment flowchart for CrCl <30 mL/min.

Design an interaction map with clarithromycin at the CYP3A4 hub and common contraindicated drugs such as simvastatin, colchicine and selected antiarrhythmics radiating out.

Add a side‑effect and monitoring checklist showing when to order LFTs, ECGs and how to report via Yellow Card.

Finally, provide images of tablet packaging and clear reconstitution and storage instructions that emphasise “discard after 14 days”.

Storage & Transport

Pharmacy And Home Handling

How should clarithromycin products be stored in the pharmacy and at home?

Tablets should be stored below 25°C and protected from light and moisture.

Label dispensed medicines to instruct patients on storage and the 14‑day discard rule for reconstituted suspension.

Advise caregivers to keep medicines out of reach of children and to shake the suspension before dosing as per the local product leaflet.

Reconstitution Notes

What must be done when preparing the oral suspension?

Reconstitute granules according to the product instructions and refrigerate the finished suspension at 2–8°C.

Inform patients to discard any unused suspension after 14 days and to measure doses accurately with an oral syringe or measuring spoon.

When transporting reconstituted suspension between clinical sites, maintain a cold chain to preserve stability.

Guidelines For Proper Use

Prescribing Checklist

What steps should clinicians follow before prescribing clarithromycin?

Confirm the indication and local susceptibility patterns and check the allergy history for macrolide hypersensitivity.

Review the full medication list for CYP3A4 and QT interactions and select the appropriate formulation for age and adherence.

Apply renal and hepatic dose adjustments as needed and document the rationale for any off‑label use.

Patient Counselling Points

How should patients be counselled when receiving clarithromycin?

Explain that improvement should be seen within 48–72 hours if the infection is susceptible and emphasise the importance of completing the full course.

Warn about common side effects such as GI upset and a metallic taste and advise on storage for tablets and the reconstituted suspension.

Ask patients to report severe symptoms such as jaundice, palpitations or severe rash immediately and advise Yellow Card reporting for serious adverse reactions.

Delivery Across United Kingdom